PHARVARIS N.V. EO -12 Market Cap ($1.67 Billion)
Market Cap & Net Worth: PHARVARIS N.V. EO -12 (9EN)
PHARVARIS N.V. EO -12 market cap. PHARVARIS N.V. EO -12 (F:9EN) has a market capitalization of $1.67 Billion (€1.43 Billion) as of November 7, 2026. Listed on the F stock exchange, this Germany-based company holds position #6567 globally and #976 in its home market, demonstrating a 2.83% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PHARVARIS N.V. EO -12's stock price €29.10 by its total outstanding shares 65407822 (65.41 Million). Also see 9EN operating cash flow for how efficiently the company converts equity into cash flow.
PHARVARIS N.V. EO -12 Market Cap History (2021–2026)
PHARVARIS N.V. EO -12 market cap history from 2021 to 2026. Data shows growth from $1.06 Billion to $2.23 Billion (5.43% CAGR). Check 9EN stock price for real-time trading data and today's change.
PHARVARIS N.V. EO -12 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PHARVARIS N.V. EO -12's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 9EN net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 9EN by Market Capitalization
Companies near PHARVARIS N.V. EO -12 in the global market cap rankings as of November 7, 2026. Also see PHARVARIS N.V. EO -12 total assets for a full breakdown of the balance sheet.
Key companies related to PHARVARIS N.V. EO -12 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of PHARVARIS N.V. EO -12 (2021–2026)
Market capitalization of PHARVARIS N.V. EO -12 from 2021 to today. Between 2021 and today, PHARVARIS N.V. EO -12's market cap moved from $1.06 Billion to $ 2.23 Billion, with a yearly change of 5.43%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €2.23 Billion | +34.72% |
| 2025 | €1.65 Billion | +18.68% |
| 2024 | €1.39 Billion | -27.20% |
| 2023 | €1.91 Billion | +142.72% |
| 2022 | €787.63 Million | -25.90% |
| 2021 | €1.06 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of PHARVARIS N.V. EO -12 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.67 Billion USD |
| MoneyControl | $1.67 Billion USD |
| MarketWatch | $1.67 Billion USD |
| marketcap.company | $1.67 Billion USD |
| Reuters | $1.67 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About PHARVARIS N.V. EO -12
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and a… Read more